Coherus Oncology, Inc.

For the period ended Dec 31, 2024. Filed Mar 17, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 17, 2025

CHRS$0.82+6.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


· · Year Ended December 31,
· · 2024 · 2023 · 2022
Net revenue	$266,960	$257,244	$211,042
Costs and expenses:
Cost of goods sold	117,553	158,992	70,083
Research and development	93,336	109,436	199,358
Selling, general and administrative	167,738	192,015	198,481
Total costs and expenses	378,627	460,443	467,922
Loss from operations	(111,667)	(203,199)	(256,880)
Interest expense	(27,158)	(40,542)	(32,474)
Gain on Sale Transactions, net (Note 6)	176,589	—	—
Loss on debt extinguishment	(12,630)	—	(6,222)
Other income (expense), net	3,373	5,469	3,822
Income (loss) before income taxes	28,507	(238,272)	(291,754)
Income tax provision (benefit)	—	(380)	—
Net income (loss)	$28,507	$(237,892)	$(291,754)

Net income (loss) per share:
Basic	$0.25	$(2.53)	$(3.76)
Diluted	$0.25	$(2.53)	$(3.76)

Weighted-average number of shares used in computing net income (loss) per share:
Basic	114,553,537	94,162,637	77,630,020
Diluted	114,830,462	94,162,637	77,630,020

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.